Get the Stockscreener App
0.2611
0.34%
-0.0009
IGC Pharma Inc stock is traded at $0.2611, with a volume of 14,570.
It is down -0.34% in the last 24 hours and down -8.32% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.262
Open:
$0.266
24h Volume:
14,570
Relative Volume:
0.03
Market Cap:
$25.97M
Revenue:
$1.20M
Net Income/Loss:
$-5.34M
P/E Ratio:
-4.2249
EPS:
-0.0618
Net Cash Flow:
$-6.27M
1W Performance:
-4.01%
1M Performance:
-8.32%
6M Performance:
-34.35%
1Y Performance:
-15.77%
1-Day Range:
$0.2612
$0.266
1-Week Range:
$0.25
$0.29
52-Week Range:
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2629 | 25.88M | 1.20M | -5.34M | -6.27M | -0.0618 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
IGC Pharma Inc Stock (IGC) Latest News
IGC Pharma, New to The Street launch 12-part national media partnership - Yahoo Finance
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning - The Daily Corinthian
Macro Review: Is IGC Pharma Inc likely to announce a buybackChart Signals & Verified Swing Trading Watchlists - baoquankhu1.vn
If You Invested $1,000 in IGC Pharma Inc (IGC) - Stock Titan
Growth Report: Does IGC Pharma Inc stock benefit from AI growthEntry Point & Technical Pattern Based Signals - baoquankhu1.vn
Ascendiant Capital maintains IGC Pharma (IGC) buy recommendation - MSN
Fund Flows: Can IGC Pharma Inc ride the EV wave2026 PreEarnings & Daily Technical Stock Forecast Reports - baoquankhu1.vn
India Globalization Capital, Inc.: Fundamental Analysis and Financial Ratings | IGC | US45408X3089 - marketscreener.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 - Hastings Tribune
IGC Achieves Major Milestone in Alzheimer's Trial Amid Financial Loss - GuruFocus
IGC Pharma’s AI-Driven Innovations and Patent Portfolio for Alzheimer’s Disease and Neuropsychiatric Treatments - Minichart
IGC to Showcase AI Platform for Alzheimer's Research at 2026 Con - GuruFocus
IGC Pharma : Annual Transition Report (Form 10-KT) - marketscreener.com
IGC Pharma (IGC) Transition 10-KT: CALMA Phase 2 shows interim agitation improvements - Stock Titan
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026 - BioSpace
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 - PharmiWeb.com
IGC Pharma to Showcase AI Platform With Alzheimer's Disease Data Initiative at ADPD 2026 - 富途牛牛
CEO Change: What is the Moat Score of IGC Pharma IncMarket Activity Recap & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IGC Pharma (NYSEAMERICAN:IGC) Stock Price Down 1.2% – Time to Sell? - Defense World
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Nasdaq
IGC Pharma Secures New Debt Financing for Liquidity - The Globe and Mail
IGC Pharma Secures ~$526K in Financing, Including Default-Convertible Note With Vanquish - TradingView
IGC Pharma (NYSE: IGC) raises cash via discounted note and $219,000 loan - Stock Titan
How IGC Pharma Inc. stock compares to growth peersDollar Strength & Smart Money Movement Tracker - Naître et grandir
EPS Watch: Should value investors consider IGC Pharma IncJuly 2025 Setups & Fast Momentum Entry Tips - baoquankhu1.vn
IGC Pharma, Inc. announced that it has received $0.307 million in funding - marketscreener.com
IGC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IGC Should I Buy - Intellectia AI
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Suppo - PharmiWeb.com
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Nasdaq
IGC PE Ratio & Valuation, Is IGC Overvalued - Intellectia AI
FOMO Trade: What is the Moat Score of IGC Pharma IncBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Trend Report: What is the Moat Score of IGC Pharma IncJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - The Globe and Mail
Aug Final Week: Is IGC Pharma Inc a cyclical or defensive stockWatch List & Real-Time Sentiment Analysis - baoquankhu1.vn
IGC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IGC Pharma expands Phase 2 CALMA trial with new clinical site - Yahoo Finance
IGC Enhances Alzheimer's Trial with New Clinical Research Collab - GuruFocus
Miami neurology network joins Alzheimer’s agitation drug trial - Stock Titan
Will IGC Pharma Inc. stock go up in YEARDay Trade & Daily Momentum Trading Reports - mfd.ru
Trend Review: Will IGC Pharma Inc benefit from green energy policiesJuly 2025 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
IGC: CALMA trial nears completion and MINT-AD AI platform set for beta launch amid favorable regulations - TradingView
IGC: Alzheimer's drug trial nears completion as AI dementia tool readies for beta launch - TradingView
Is IGC Pharma Inc. stock a buy before product launchesJuly 2025 Movers & Long Hold Capital Preservation Tips - mfd.ru
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - GuruFocus
Low-dose THC Alzheimer’s drug from IGC wins key North America patent - Stock Titan
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Finviz
Is IGC Pharma Inc. likely to announce a buybackJuly 2025 Market Mood & Daily Entry Point Alerts - mfd.ru
Aug Catalysts: Should I trade or invest in IGC Pharma IncJuly 2025 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Why IGC Pharma Inc. (IGS1) stock could rally stronglyJuly 2025 Breakouts & Accurate Entry and Exit Point Alerts - mfd.ru
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):